Carlo Allegri | Reuters See the companies making headlines in midday trading. Bed Bath & Beyond, AMC — Shares rose 41% and 13% respectively as social media traders appeared to invest in the two meme stocks, even without an apparent catalyst. Signify Health — The stock jumped 13% after the Wall Street Journal reported, citing people familiar with the matter, that CVS Health is planning a bid for the home health services company. First Solar — First Solar jumped 5% after Goldman Sachs upgraded shares to overweight from neutral. The bank said the solar tech stock should benefit from the passage of the deflationary law and raised its price target to $126 from $83 a share. Rhythm Pharmaceuticals — The biopharmaceutical company’s stock gained 7% after Goldman Sachs upgraded it to buy from neutral, saying shares could rise about 40% after successful trials of its obesity drug. Barrick Gold — The miner jumped 5% after beating analysts’ expectations in second-quarter results on higher copper output. Palantir Technologies — Shares of Palantir fell more than 13% after the software company known for working with the government reported a loss of 1 cent per share in the most recent quarter. Analysts had expected earnings of 3 cents per share, according to Refinitiv. CFO David Glazer told CNBC that the company’s weakness was due to a decline in investments and marketable securities. Tyson Foods — Shares of the food products company fell 8% after Tyson missed estimates for third-quarter earnings. Company executives said on an investor call that supply chain issues are hurting its ability to fulfill customer orders, according to a transcript of the call by FactSet. Nvidia — The semiconductor stock fell more than 8% after Nvidia reported a revenue loss in its second-quarter results. The chipmaker reported revenue of $6.7 billion, compared with analysts’ expectations of $8.1 billion, citing weakness in gaming. BioNTech — The German biotech company, which partnered with Pfizer on a Covid-19 vaccine, fell 9% after reporting earnings and revenue that missed expectations. The company said the variant-adapted Covid-19 vaccine should boost demand in the fourth quarter. — CNBC’s Tanaya Macheel, Jesse Pound, Samantha Subin and Michelle Fox Theobald contributed reporting
